Cargando…
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
BACKGROUND: Response to immune checkpoint blockade (ICB) in ovarian cancer remains disappointing. Several studies have identified the chemokine CXCL9 as a robust prognosticator of improved survival in ovarian cancer and a characteristic of the immunoreactive subtype, which predicts ICB response. How...
Autores principales: | Seitz, Stefanie, Dreyer, Tobias F., Stange, Christoph, Steiger, Katja, Bräuer, Rosalinde, Scheutz, Leandra, Multhoff, Gabriele, Weichert, Wilko, Kiechle, Marion, Magdolen, Viktor, Bronger, Holger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090786/ https://www.ncbi.nlm.nih.gov/pubmed/35314795 http://dx.doi.org/10.1038/s41416-022-01763-0 |
Ejemplares similares
-
Induction of cathepsin B by the CXCR3 chemokines CXCL9 and CXCL10 in human breast cancer cells
por: Bronger, Holger, et al.
Publicado: (2017) -
Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer
por: Gong, Weiwei, et al.
Publicado: (2020) -
Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors
por: Bronger, Holger, et al.
Publicado: (2019) -
CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer
por: Bronger, Holger, et al.
Publicado: (2016) -
Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer
por: Geng, Xiaocong, et al.
Publicado: (2017)